Novavax (NVAX +8.7%) raises ~$200 million from the direct sale of ~4.4M shares of Series A convertible preferred stock to RA Capital (~$45.57/share).
The capital will help fund the advancement of its COVID-19 vaccine candidate and flu vaccine NanoFlu.
Closing date was June 12.
https://seekingalpha.com/news/3583051-novavax-raises-200-million-to-advance-vaccine-candidates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.